Pazopanib

Search with Google Search with Bing

Information
Drug Name
Pazopanib
Description
Entry(CIViC)
10
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
sarcoma TP53 DELETERIOUS MUTATION TP53 DELETERIOUS MUTATION B Predictive Supports Sensitivity/Response Somatic 2 26646755 Detail
transitional cell carcinoma MTOR E2014K + E2419K MTOR E2014K + E2419K C Predictive Supports Sensitivity/Response Somatic 2 24625776 Detail
transitional cell carcinoma FGFR3 p.Ser249Cys (p.S249C)
( ENST00000340107.9, ENST00000352904.6, ENST00000412135.7, ENST00000440486.8, ENST00000481110.7 ) FGFR3 p.Ser249Cys (p.S249C)
( ENST00000412135.7, ENST00000340107.9, ENST00000440486.8, ENST00000352904.6, ENST00000481110.7 ) 		C Predictive Supports Sensitivity/Response Somatic 2 25766722 Detail
renal cell carcinoma VHL LOSS-OF-FUNCTION VHL LOSS-OF-FUNCTION B Predictive Does Not Support Sensitivity/Response Somatic 2 23881929 Detail
renal cell carcinoma EPAS1 OVEREXPRESSION
( ENST00000263734.5 ) EPAS1 OVEREXPRESSION
( ENST00000263734.5 ) 		B Predictive Does Not Support N/A Somatic 3 23881929 Detail
renal cell carcinoma HIF1A EXPRESSION HIF1A EXPRESSION B Predictive Does Not Support N/A N/A 2 23881929 Detail
cholangiocarcinoma FGFR2 FGFR2-TACC3 C Predictive Supports Sensitivity/Response Somatic 3 24550739 Detail
bladder carcinoma MTOR MUTATION MTOR MUTATION C Predictive Supports Sensitivity/Response Somatic 3 24625776 Detail
breast cancer FGFR1 AMPLIFICATION
( ENST00000425967.8 ) FGFR1 AMPLIFICATION
( ENST00000425967.8 ) 		C Predictive Supports Sensitivity/Response Somatic 2 29223982 Detail
adenosquamous lung carcinoma FGFR1 AMPLIFICATION
( ENST00000425967.8 ) FGFR1 AMPLIFICATION
( ENST00000425967.8 ) 		C Predictive Supports Sensitivity/Response Somatic 3 24302556 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
19 advanced sarcoma patients treated with pazopani... TP53 TP53 DELETERIOUS MUTATION TP53 DELETERIOUS MUTATION Sensitivity true CIViC Evidence detail
A phase 1 clinical trial identified a patient with... MTOR MTOR E2014K + E2419K MTOR E2014K + E2419K Sensitivity true CIViC Evidence detail
Case report of a 67 year old woman with high-grade... FGFR3 FGFR3 p.Ser249Cys (p.S249C)
( ENST00000340107.9, ENST00000352904.6, ENST00000412135.7, ENST00000440486.8, ENST00000481110.7 ) FGFR3 p.Ser249Cys (p.S249C)
( ENST00000412135.7, ENST00000340107.9, ENST00000440486.8, ENST00000352904.6, ENST00000481110.7 ) 		Sensitivity true CIViC Evidence detail
VHL mutations were evaluated in 78 tumors samples ... VHL VHL LOSS-OF-FUNCTION VHL LOSS-OF-FUNCTION Sensitivity false CIViC Evidence detail
HIF-2A (EPAS1) staining was conducted on 66 tumors... EPAS1 EPAS1 OVEREXPRESSION
( ENST00000263734.5 ) EPAS1 OVEREXPRESSION
( ENST00000263734.5 ) 		N/A false CIViC Evidence detail
Immunohistochemical staining was performed on 65 p... HIF1A HIF1A EXPRESSION HIF1A EXPRESSION N/A false CIViC Evidence detail
In a 43 year old female patient with this fusion i... FGFR2 FGFR2 FGFR2-TACC3 Sensitivity true CIViC Evidence detail
A case-study of a patient with urothelial carcinom... MTOR MTOR MUTATION MTOR MUTATION Sensitivity true CIViC Evidence detail
Case report in a HR positive, Her2/neu negative br... FGFR1 FGFR1 AMPLIFICATION
( ENST00000425967.8 ) FGFR1 AMPLIFICATION
( ENST00000425967.8 ) 		Sensitivity true CIViC Evidence detail
Patient diagnosed with metastatic squamous cell lu... FGFR1 FGFR1 AMPLIFICATION
( ENST00000425967.8 ) FGFR1 AMPLIFICATION
( ENST00000425967.8 ) 		Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT02009449 Active, not recruiting Phase 1 A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors November 15, 2013 August 25, 2024
NCT03260894 Active, not recruiting Phase 3 Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) December 7, 2017 December 31, 2024
NCT02203760 Active, not recruiting Phase 2 Pazopanib vs. Pazopanib Plus Gemcitabine October 16, 2019 December 31, 2024
NCT01217931 Active, not recruiting Phase 2 Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial January 19, 2011 January 31, 2025
NCT02180867 Active, not recruiting Phase 2/Phase 3 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery July 11, 2014 December 22, 2024
NCT00370513 Completed Phase 1 A Phase I Study of Pazopanib in Adult Patients With Liver Cancer December 6, 2006 April 8, 2009
NCT00387205 Completed Phase 1 Study To Assess Long Term Safety Of Pazopanib June 20, 2006 March 8, 2018
NCT00387387 Completed Phase 1 Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin) October 20, 2006 August 14, 2009
NCT00387764 Completed Phase 3 Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer September 2006 October 2012
NCT00388076 Completed Phase 1 Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB) April 28, 2006 July 21, 2009
NCT00516672 Completed Phase 1 Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors September 10, 2007 October 14, 2015
NCT00540943 Completed Phase 1 Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer July 13, 2007 May 3, 2010
NCT00558103 Completed Phase 2 Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer December 2007 December 2011
NCT00612456 Completed Phase 2 To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD March 5, 2008 June 17, 2009
NCT00619424 Completed Phase 1 A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors November 15, 2007 September 4, 2009
NCT00674024 Completed Phase 1 Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function October 7, 2008 January 22, 2013
NCT00720941 Completed Phase 3 Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma August 14, 2008 March 24, 2021
NCT00731211 Completed Phase 2 Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma September 2008 September 2012
NCT00732420 Completed Phase 1 Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors September 24, 2008 June 12, 2013
NCT00733304 Completed Phase 2 An Extension to Study MD7108240 June 25, 2008 September 9, 2009
NCT00753688 Completed Phase 3 Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy October 2008 December 2012
NCT00775307 Completed Phase 2/Phase 3 Adjuvant Pazopanib in Stage I NSCLC November 2008 April 18, 2016
NCT00800345 Completed Phase 1 Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors April 2009 September 2015
NCT00827372 Completed Phase 2 A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer January 2009 July 2010
NCT00861029 Completed Phase 1 VEG111485: A QTc Study of Pazopanib March 19, 2009 February 15, 2010
NCT00866528 Completed Phase 1 Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer July 9, 2009 October 25, 2012
NCT00866697 Completed Phase 3 Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer May 26, 2009 August 24, 2017
NCT01027598 Completed Phase 2 Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer January 2010 June 2014
NCT01064310 Completed Phase 3 Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer May 17, 2010 November 23, 2015
NCT01072214 Completed Phase 1 A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers March 9, 2010 June 28, 2010
NCT01099540 Completed Phase 2 Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor April 2010 March 2013
NCT01147822 Completed Phase 2 Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma May 19, 2010 September 3, 2021
NCT01154062 Completed Phase 1 A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration August 16, 2010 April 29, 2011
NCT00297258 Completed Phase 2 Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma November 2005 February 2014
NCT01184326 Completed Phase 1 Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer January 2011 March 2017
NCT01205230 Completed Phase 4 VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK September 2010 August 2011
NCT01165385 Completed Phase 1 Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors June 2010 October 2014
NCT00334282 Completed Phase 3 Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma April 2006 December 2014
NCT00350727 Completed Phase 2 Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma December 2006 December 2009
NCT00358384 Completed Phase 1 Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034 September 26, 2005 February 24, 2006
NCT00367679 Completed Phase 2 Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer November 2006 April 2008
NCT01392183 Completed Phase 2 Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) October 24, 2012 September 8, 2019
NCT01408004 Completed Phase 2 Rotating Pazopanib and Everolimus to Avoid Resistance November 2011 April 2014
NCT01430572 Completed Phase 1 Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients October 7, 2011 May 12, 2020
NCT01438554 Completed Phase 1 Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma October 2011 August 2018
NCT01446224 Completed Cardiovascular and Torsades de Pointes Monitoring for Pazopanib December 2010 December 2013
NCT01454804 Completed Phase 1 Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors October 2011 March 2015
NCT01466972 Completed Phase 2 Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib April 27, 2012 October 2, 2019
NCT01468922 Completed Phase 1 Pazopanib and ARQ 197 for Advanced Solid Tumors January 23, 2012 February 11, 2016
NCT01472081 Completed Phase 1 Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) February 9, 2012 June 3, 2021
NCT01503372 Completed Phase 2 FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer November 2011 December 14, 2017
NCT01506596 Completed Phase 2 Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma March 2012 March 2016
NCT01521715 Completed Phase 4 First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma January 24, 2012 July 31, 2017
NCT01524848 Completed Phase 2 Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib February 2012 November 2016
NCT01532687 Completed Phase 2 Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma March 13, 2012 October 31, 2019
NCT01538238 Completed Phase 2 pazopanib_NCRCC,Ph2 STUDY May 2, 2012 November 14, 2015
NCT01566747 Completed Phase 2 Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5 March 2011 July 15, 2020
NCT01610206 Completed Phase 2 A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer September 2012 December 31, 2020
NCT01636908 Completed N/A Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. August 2011 December 1, 2019
NCT01639911 Completed Phase 1 Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors August 14, 2013 July 28, 2016
NCT01644825 Completed Phase 2 Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer December 2010 December 29, 2015
NCT01649778 Completed Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma July 19, 2012 July 3, 2017
NCT01692496 Completed Phase 2 Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial January 29, 2013 March 2, 2018
NCT01713296 Completed Phase 2 Pazopanib in Relapsed and Refractory Small Cell Lung Cancer November 2011 March 2015
NCT01716416 Completed Phase 1 Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) May 31, 2013 August 31, 2017
NCT01719302 Completed Phase 1/Phase 2 Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma October 2012 April 2015
NCT01743482 Completed Phase 2 Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors May 17, 2013 July 27, 2016
NCT01797874 Completed Phase 2 Pazopanib Maintenance for SCLC June 2013 December 2017
NCT01832259 Completed Phase 2 A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection August 2013 August 9, 2018
NCT01861951 Completed Phase 2 A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma October 2012 July 11, 2017
NCT01931098 Completed Phase 2 Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab December 10, 2015 September 12, 2019
NCT01956669 Completed Phase 2 Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors October 8, 2014 November 5, 2019
NCT01985295 Completed Phase 1 Combined Modality Treatment of Sarcomas of the Extremities June 2010 November 2014
NCT01995981 Completed Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS December 2013 November 10, 2017
NCT02014636 Completed Phase 1 Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018) December 27, 2013 February 27, 2019
NCT02066285 Completed Phase 2 Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma June 2014 March 24, 2023
NCT02138526 Completed Phase 1 Pazopanib Tolerability When Given With Food June 2014 November 2018
NCT02282579 Completed Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy October 2014 April 2015
NCT02300545 Completed Phase 2 Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy April 8, 2015 July 11, 2020
NCT02383251 Completed Phase 2 Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer June 15, 2015 December 31, 2020
NCT02393820 Completed Phase 2 Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma August 26, 2013 October 2019
NCT02406521 Completed Phase 1 Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets April 2015 December 31, 2019
NCT02450136 Completed N/A Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors October 8, 2015 February 2018
NCT02555748 Completed Phase 4 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma November 17, 2015 January 16, 2020
NCT02691767 Completed N/A Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors May 2016 February 13, 2020
NCT02729194 Completed Early Phase 1 Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma June 2016 September 2017
NCT02960906 Completed Phase 2 A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer May 31, 2017 February 15, 2021
NCT03139331 Completed Phase 1 PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma June 6, 2017 September 30, 2020
NCT03200717 Completed Phase 2 Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment November 14, 2017 August 10, 2021
NCT04462445 Completed Phase 2 Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb June 25, 2015 February 8, 2017
NCT01221506 Completed Early Phase 1 Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC) October 2010 April 2019
NCT01227928 Completed Phase 2 Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women September 2010 January 2014
NCT01235962 Completed Phase 3 A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) November 30, 2010 April 15, 2019
NCT01238770 Completed Phase 1/Phase 2 Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer November 2010 October 2015
NCT01253369 Completed Phase 2 Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer June 2010 December 2014
NCT01262014 Completed Phase 2 Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian Cancer December 2010 December 2015
NCT01262820 Completed Phase 2 Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab December 2010 October 2014
NCT01280201 Completed Phase 2 Pazopanib as Single Agent in Advanced NETs January 26, 2011 March 15, 2015
NCT01323400 Completed Phase 2 Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) March 2011 February 2016
NCT01330966 Completed Phase 2 Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma April 2011 February 2018
NCT01339871 Completed Phase 1 Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies April 20, 2011 June 7, 2017
NCT01361113 Completed Phase 2 Neoadjuvant Pazopanib in Renal Cell Carcinoma June 2011 February 15, 2017
NCT01361334 Completed Phase 2 Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible June 2011 March 2016
NCT01385228 Completed Phase 1 Pazopanib, Docetaxel, Prednisone Prostate June 2011 February 2016
NCT02354612 No longer available Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial
NCT06263231 Not yet recruiting Phase 3 A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) June 2024 December 2028
NCT03628131 Not yet recruiting Phase 1/Phase 2 Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors October 2018 July 2025
NCT03850730 Not yet recruiting Phase 1/Phase 2 Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia July 1, 2023 December 31, 2025
NCT04199026 Not yet recruiting Early Phase 1 Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma January 31, 2025 December 31, 2025
NCT05949424 Not yet recruiting Phase 4 OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults May 2024 March 2025
NCT03571438 Recruiting N/A Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors October 16, 2017 September 30, 2024
NCT03850964 Recruiting Phase 2/Phase 3 Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz) May 8, 2023 March 31, 2026
NCT05180695 Recruiting Phase 1/Phase 2 HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas April 15, 2022 July 2026
NCT03592472 Recruiting Phase 3 A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) July 17, 2018 June 30, 2025
NCT02331498 Recruiting Phase 1/Phase 2 Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme June 2015 August 2030
NCT06239272 Recruiting Phase 1/Phase 2 NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) March 27, 2024 June 2037
NCT05432791 Suspended Phase 2/Phase 3 Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working March 30, 2023 March 9, 2030
NCT01407562 Terminated Phase 1 Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors September 17, 2010 March 29, 2016
NCT02089802 Terminated Phase 2 Optimizing Pazopanib Exposure in RCC Patients February 25, 2014 March 22, 2016
NCT02113826 Terminated Phase 2 Pazopanib for Metastatic Alveolar Soft Part Sarcoma April 2014 November 2017
NCT01059656 Terminated Phase 2 Phase II Pazopanib Study in Advanced Dermatofibrosarcomas July 2010 April 2014
NCT02193152 Terminated Phase 2 Pazopanib in Molecularly Selected Patients With Advanced NSCLC April 27, 2015 December 24, 2019
NCT01035658 Terminated Phase 1/Phase 2 Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma January 2010 March 2014
NCT02204371 Terminated Phase 2 Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia February 25, 2015 February 10, 2016
NCT02207309 Terminated Phase 2 Pazopanib Maintenance Phase II June 22, 2015 July 29, 2016
NCT01080248 Terminated Phase 2 Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer August 2010 October 2011
NCT01012362 Terminated Phase 1 Study of Pazopanib and Ixabepilone in Patients With Solid Tumors December 2009 February 2013
NCT01542047 Terminated Phase 1 A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies August 2012 July 2013
NCT01543802 Terminated Phase 2 Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma April 2013 October 2016
NCT01548144 Terminated Phase 1 Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer April 2012 August 26, 2021
NCT02279576 Terminated Phase 2 Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG) January 2015 September 2016
NCT01716546 Terminated Phase 1/Phase 2 Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer July 2011 January 2015
NCT02560012 Terminated Phase 2 Personalized Targeted Inhibitors Treatment in Renal Cell Cancer January 4, 2016 July 27, 2017
NCT02575066 Terminated Phase 2 Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients March 17, 2016 March 20, 2019
NCT01759303 Terminated Phase 2 Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung April 2013 May 2017
NCT02601209 Terminated Phase 1/Phase 2 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma November 30, 2015 July 11, 2022
NCT01313663 Terminated Phase 2 A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population February 2011 July 2012
NCT02795819 Terminated Phase 1 Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer July 8, 2016 March 14, 2019
NCT02959554 Terminated Phase 2 Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control December 2016 January 2021
NCT01060514 Terminated Phase 1 Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer February 2010 September 2013
NCT01391611 Terminated Phase 2 Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST) July 2011 December 2013
NCT02055690 Terminated Phase 1/Phase 2 PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer September 2014 November 24, 2017
NCT01392352 Terminated Phase 2 HYPAZ: Hypertension Induced by Pazopanib April 2011 September 2015
NCT01622660 Terminated Phase 2 Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy June 2012 February 2016
NCT01642017 Terminated Phase 1 Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria November 22, 2012 March 2018
NCT01377298 Unknown status Phase 2 Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma June 2011 May 2014
NCT02638428 Unknown status Phase 2 Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy December 2015 December 2023
NCT02324803 Unknown status Phase 2 Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients July 2014 December 2015
NCT01577784 Unknown status Phase 2 Pazopanib in Second-line Therapy in Renal Cell Carcinoma April 2012 October 2015
NCT02348398 Withdrawn Phase 2 Phase II Study of Pazopanib and Topotecan in Cervical Cancer August 2016
NCT02342600 Withdrawn Phase 2 SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor) January 2017
NCT02378142 Withdrawn Phase 2 Pazopanib for Treating Uterine Leiomyosarcoma March 2015
NCT03149120 Withdrawn Phase 2 Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas August 2017 June 2022